Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway

Annals of the Rheumatic Diseases

Volumn 70, Issue 11, 2011, Pages 2029-2036

  Higgs, Brandon W ^a   Liu, Zheng ^a   White, Barbara ^a   Zhu, Wei ^a   White, Wendy I ^a   Morehouse, Chris ^a   Brohawn, Philip ^a   Kiener, Peter A ^a   Richman, Laura ^a   Fiorentino, David ^b   Greenberg, Steven A ^c   Jallal, Bahija ^a   Yao, Yihong ^a  

^a MEDIMMUNE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DERMATOMYOSITIS; DISEASE ACTIVITY; FEMALE; GENE IDENTIFICATION; GENE LOCATION; GENE OVEREXPRESSION; GENETIC CORRELATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MARKER GENE; MICROARRAY ANALYSIS; POLYMYOSITIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCLERODERMA; SYSTEMIC LUPUS ERYTHEMATOSUS; TISSUE DISTRIBUTION; TRANSCRIPTION INITIATION; TYPE 1 IFN GENE;

ADULT; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BLOOD PROTEINS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INTERFERON TYPE I; INTERFERON-ALPHA; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MYOSITIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RHEUMATIC DISEASES; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION;

EID: 80053495592     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2011.150326     Document Type: Article

References (40)

1. Kavanaugh A . Interleukin-6 inhibition and clinical effi cacy in rheumatoid arthritis treatment-data from randomized clinical trials. Bull NYU Hosp Jt Dis 2007;65(Suppl 1):S16-20.
2. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85. (Pubitemid 43736578)
3. Ratner M . Human Genome Sciences trial data wow lupus community. Nat Biotechnol 2009;27:779-80.
4. Theofilopoulos A N, Baccala R, Beutler B, et al. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 2005;23:307-36. (Pubitemid 40563172)
5. Bengtsson A A, Sturfelt G, Truedsson L, et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000;9:664-71. (Pubitemid 32011791)
6. Hooks J J, Moutsopoulos HM, Geis SA, et al. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979;301:5-8. (Pubitemid 9226519)
7. Crow M K. Interferon-alpha: a new target for therapy in systemic lupus erythematosus? Arthritis Rheum 2003;48:2396-401. (Pubitemid 37129415)
8. Yao Y, Richman L, Higgs BW, et al. Neutralization of interferon-alpha/ beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009;60:1785-96.
9. Wallace D, Petri M, Olsen N, et al. MEDI-545, an anti-interferon alpha monoclonal antibody, shows evidence of clinical activity in systemic lupus erythematosus. Arthritis Rheum 2007;56:S526-7.
10. Walsh RJ, Kong SW, Yao Y, et al. Type I interferon-inducible gene expression in blood is present and refl ects disease activity in dermatomyositis and polymyositis. Arthritis Rheum 2007;56:3784-92. (Pubitemid 350100711)
11. Greenberg SA, Pinkus JL, Pinkus GS, et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005;57:664-78. (Pubitemid 40628855)
12. van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, et al. Rheumatoid arthritis subtypes identifi ed by genomic profi ling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis 2007;66:1008-14.
13. Båve U, Nordmark G, Lövgren T, et al. Activation of the type I interferon system in primary Sjögren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 2005;52:1185-95. (Pubitemid 40530126)
14. Assassi S, Mayes MD, Arnett FC, et al. Systemic sclerosis and lupus: points in an interferon-mediated continuum. Arthritis Rheum 2010;62:589-98.
15. Yao Y, Higgs BW, Morehouse C, et al. Development of potential pharmacodynamic and diagnostic markers for anti-IFN-a monoclonal antibody trials in systemic lupus erythematosus. Hum Genomics Proteomics 2009;2009:pii:374312.
16. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classifi cation of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7. (Pubitemid 13221242)
17. Hochberg M C. Updating the American College of Rheumatology revised criteria for the classifi cation of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
18. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
19. Yao Y, Richman L, Morehouse C, et al. Type I interferon: potential therapeutic target for psoriasis? PLoS ONE 2008;3:e2737.
20. Mavragani CP, La DT, Stohl W, et al. Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort. Arthritis Rheum 2010;62:392-401.
21. Niewold TB, Adler JE, Glenn SB, et al. Age- and sex-related patterns of serum interferon-alpha activity in lupus families. Arthritis Rheum 2008;58:2113-19. (Pubitemid 351988103)
22. LaVange LM, Koch GG. Rank score tests. Circulation 2006;114:2528-33. (Pubitemid 44901526)
23. Der SD, Zhou A, Williams BR, et al. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci USA 1998;95:15623-8. (Pubitemid 29018750)
24. Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003;197:711-23. (Pubitemid 36350866)
25. Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003;100:2610-15. (Pubitemid 36297546)
26. Rönnblom L, Alm GV. A pivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus. J Exp Med 2001;194:F59-63. (Pubitemid 34028649)
27. Crow MK. Interferon-alpha: a therapeutic target in systemic lupus erythematosus. Rheum Dis Clin North Am 2010;36:173-86, x.
28. Tezak Z, Hoffman EP, Lutz JL, et al. Gene expression profi ling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis. J Immunol 2002;168:4154-63. (Pubitemid 34298424)
29. Greenberg SA. Type 1 interferons and myositis. Arthritis Res Ther 2010;12(Suppl 1):S4.
30. Fiorentino DF. Type I interferon in the induction or exacerbation of dermatomyositis: what this observation tells us about the naturally occurring disease. Arch Dermatol 2008;144:1379-82.
31. Gottenberg JE, Cagnard N, Lucchesi C, et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome. Proc Natl Acad Sci USA 2006;103:2770-5.
32. Emamian ES, Leon JM, Lessard CJ, et al. Peripheral blood gene expression profiling in Sjögren's syndrome. Genes Immun 2009;10:285-96.
33. Conigliaro P, Perricone C, Benson RA, et al. The type I IFN system in rheumatoid arthritis. Autoimmunity 2010;43:220-5.
34. van der Pouw Kraan TC, van Baarsen LG, Wijbrandts CA, et al. Expression of a pathogen-response program in peripheral blood cells defi nes a subgroup of rheumatoid arthritis patients. Genes Immun 2008;9:16-22. (Pubitemid 351150030)
35. van Baarsen LG, Bos WH, Rustenburg F, et al. Gene expression profi ling in autoantibody-positive patients with arthralgia predicts development of arthritis. Arthritis Rheum 2010;62:694-704.
36. Kim D, Peck A, Santer D, et al. Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fi brosis. Arthritis Rheum 2008;58:2163-73. (Pubitemid 351988110)
37. Coelho LF, De Oliveira JG, Kroon EG. Interferons and scleroderma-a new clue to understanding the pathogenesis of scleroderma? Immunol Lett 2008;118:110-15.
38. Bilgic H, Ytterberg SR, Amin S, et al. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum 2009;60:3436-46.
39. Eloranta ML, Franck-Larsson K, Lövgren T, et al. Type I interferon system activation and association with disease manifestations in systemic sclerosis. Ann Rheum Dis 2010;69:1396-402.
40. Sekiguchi N, Kawauchi S, Furuya T, et al. M essenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab. Rheumatology (Oxford) 2008;47:780-8. (Pubitemid 351796361)